EMILY HARBARGER: Open Payments
NPI 1568020675 · BRANDON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,910 in 102 payments from 16 companies in 2025. Trend: 2023 $2,337 · 2024 $2,026 · 2025 $1,910
Food & beverage: $1,910
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 20 | $374 |
| Corcept Therapeutics | 11 | $292 |
| ABBVIE INC. | 16 | $287 |
| PFIZER INC. | 9 | $164 |
| AstraZeneca Pharmaceuticals LP | 9 | $162 |
| GlaxoSmithKline, LLC. | 8 | $144 |
| Lilly USA, LLC | 6 | $127 |
| Amgen Inc. | 6 | $87 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $69 |
| Abbott Laboratories | 3 | $63 |
Products named: Korlym, FARXIGA, Wegovy, VRAYLAR, TRELEGY ELLIPTA, UBRELVY, PREVNAR 20, Ozempic.
Industry payments across MS — which companies pay providers there.
